Point72 Asia Singapore Pte. Ltd. Raises Stock Holdings in DaVita Inc. (NYSE:DVA)

Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of DaVita Inc. (NYSE:DVA) by 60.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,498 shares of the company’s stock after purchasing an additional 563 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in DaVita were worth $208,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Franklin Resources Inc. increased its stake in shares of DaVita by 42.0% in the fourth quarter. Franklin Resources Inc. now owns 7,866 shares of the company’s stock worth $824,000 after buying an additional 2,325 shares during the last quarter. Treasurer of the State of North Carolina raised its stake in shares of DaVita by 1.0% in the 4th quarter. Treasurer of the State of North Carolina now owns 24,737 shares of the company’s stock valued at $2,591,000 after purchasing an additional 234 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of DaVita by 4.2% during the fourth quarter. California State Teachers Retirement System now owns 87,217 shares of the company’s stock worth $9,137,000 after purchasing an additional 3,543 shares during the last quarter. KBC Group NV increased its holdings in DaVita by 123.8% in the fourth quarter. KBC Group NV now owns 107,021 shares of the company’s stock valued at $11,212,000 after buying an additional 59,202 shares during the last quarter. Finally, Royal London Asset Management Ltd. increased its holdings in shares of DaVita by 1.1% in the 4th quarter. Royal London Asset Management Ltd. now owns 21,024 shares of the company’s stock valued at $2,202,000 after acquiring an additional 227 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock worth $27,387,069 over the last ninety days. Company insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on DVA shares. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Truist Financial increased their price target on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Tuesday, August 20th. TD Cowen boosted their price objective on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. UBS Group increased their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Finally, Bank of America boosted their price target on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $157.00.

DaVita Trading Down 2.2 %

NYSE:DVA opened at $159.15 on Thursday. The stock has a market cap of $13.96 billion, a price-to-earnings ratio of 18.09, a PEG ratio of 0.93 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $166.04. The business has a fifty day moving average of $151.34 and a 200-day moving average of $142.64.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.47 by $0.12. The firm had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. DaVita’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $2.08 EPS. Equities analysts predict that DaVita Inc. will post 9.99 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.